Eris Lifesciences Ltd
NSE:ERIS

Watchlist Manager
Eris Lifesciences Ltd Logo
Eris Lifesciences Ltd
NSE:ERIS
Watchlist
Price: 1 468.2 INR -2.9% Market Closed
Market Cap: 199.9B INR

Eris Lifesciences Ltd
Investor Relations

Nestled in the competitive landscape of India's pharmaceutical sector, Eris Lifesciences Ltd. has carved a niche for itself by focusing intently on the domestic market, predominantly within the specialty prescription segment. Founded in 2007 by Amit Bakshi, the company has distinguished itself with a strategy that emphasizes building relationships with medical professionals through a robust field force, eschewing the conventional tactic of overwhelming physicians with a vast army of generic products. Eris opts for precision, targeting chronic and lifestyle-related ailments such as diabetes, cardiology, and neurology. This focus on long-term therapies aligns with the rising demand for healthcare tailored to the aging population's needs and the increase in lifestyle diseases in India, thus ensuring a steady stream of revenue.

The brilliance of Eris Lifesciences' business model is reflected in its comprehensive distribution network and a well-coordinated supply chain that covers a significant portion of Indian urban centers. By manufacturing many of its products in-house, Eris maintains control over production quality and cost – a strategic move that bolsters its pricing power in the competitive generics market. The company also adeptly tweaks its offerings and strategies based on physician feedback and market trends, ensuring relevance and resonance with its target segments. This model is not about flooding the market with a plethora of offerings; it's about precision placement with specialized therapeutic products that meet specific, high-demand needs – a strategy that has consistently translated into tangible financial growth.

Show more
Loading

Earnings Calls

2024 Q4
Mar 14, 2025
Show Transcript
Previous
Next
Mach Natural Resources Expects Revenue Growth and Increased Production in 2025
2024 Q4
Mar 14, 2025

In the latest earnings call, Mach Natural Resources reported strong production results with 86,700 BOE per day, despite facing low natural gas prices. The company plans to increase its drilling activity from two to three rigs in 2025, focusing on high-return wells while maintaining a reinvestment rate below 50%. With anticipated spending of $225-$240 million, they expect stable production. Additionally, the company is confident in achieving continued revenue growth due to improved natural gas prices. Their disciplined acquisition strategy remains central to driving shareholder returns, with a strong emphasis on maintaining financial strength.

Show Full Analysis

Management

Mr. Amit Indubhushan Bakshi
Chairman & MD
No Bio Available
Mr. Sachin Shah
Chief Financial Officer
No Bio Available
Mr. Krishnakumar Vaidyanathan
Executive Director & COO
No Bio Available
Mr. Gagan Atreja
President of Sales & Marketing
No Bio Available
Mr. Inderjeet Singh Negi
Executive Director
No Bio Available
Mr. Kaushal Kamlesh Shah
Whole Time Director
No Bio Available
Mr. Deepak Kapoor
Senior Vice President
No Bio Available
Mr. Milind Talegaonkar
Compliance Officer & Company Secretary
No Bio Available
Mr. Vijay S. Joshi
President Medical
No Bio Available
Mr. Manish Kapoor
Vice President
No Bio Available

Contacts

Address
GUJARAT
Ahmedabad
8th Floor, Commerce House- IV,, Prahladnagar, 100 ft road
Contacts
+917930451111
www.eris.co.in